199 related articles for article (PubMed ID: 26813447)
21. Prolonging the duration of masseter muscle reduction by adjusting the masticatory movements after the treatment of masseter muscle hypertrophy with botulinum toxin type a injection.
Wei J; Xu H; Dong J; Li Q; Dai C
Dermatol Surg; 2015 Jan; 41 Suppl 1():S101-9. PubMed ID: 25548838
[TBL] [Abstract][Full Text] [Related]
22. Bilateral temporalis muscle hypertrophy: a case report.
Da Silva K; Mandel L
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Jul; 102(1):e1-3. PubMed ID: 16831662
[TBL] [Abstract][Full Text] [Related]
23. Treatment of unilateral masseteric hypertrophy with botulinum toxin: case report.
Mandel L; Tharakan M
J Oral Maxillofac Surg; 1999 Aug; 57(8):1017-9. PubMed ID: 10437733
[No Abstract] [Full Text] [Related]
24. Masseter muscle fibre changes following reduction of masticatory function.
Tsai CY; Lin YC; Su B; Yang LY; Chiu WC
Int J Oral Maxillofac Surg; 2012 Mar; 41(3):394-9. PubMed ID: 22103999
[TBL] [Abstract][Full Text] [Related]
25. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement.
To EW; Ahuja AT; Ho WS; King WW; Wong WK; Pang PC; Hui AC
Br J Plast Surg; 2001 Apr; 54(3):197-200. PubMed ID: 11254408
[TBL] [Abstract][Full Text] [Related]
26. Literature review of the adverse events associated with botulinum toxin injection for the masseter muscle hypertrophy.
Yeh YT; Peng JH; Peng HP
J Cosmet Dermatol; 2018 Oct; 17(5):675-687. PubMed ID: 30091170
[TBL] [Abstract][Full Text] [Related]
27. The medical management of masseteric hypertrophy with botulinum toxin.
Finn S; Ryan P; Sleeman D
J Ir Dent Assoc; 2000; 46(3):84-6. PubMed ID: 11323940
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Botulinum Toxin in Treating Asian Indian Patients with Masseter Hypertrophy: A 4-Year Follow-Up Study.
Shome D; Khare S; Kapoor R
Plast Reconstr Surg; 2019 Sep; 144(3):390e-396e. PubMed ID: 31461011
[TBL] [Abstract][Full Text] [Related]
29. Evaluation and selecting indications for the treatment of improving facial morphology by masseteric injection of botulinum toxin type A.
Gaofeng L; Jun T; Bo P; Bosheng Z; Qian Z; Dongping L
J Plast Reconstr Aesthet Surg; 2010 Dec; 63(12):2026-31. PubMed ID: 20116356
[TBL] [Abstract][Full Text] [Related]
30. Anatomical Considerations When Treating Compensatory Hypertrophy of the Upper Part of the Masseter after Long-Term Botulinum Neurotoxin Type A Injections.
Lee KL; Cho HJ; Bae H; Park HJ; Park MS; Kim HJ
Toxins (Basel); 2020 Mar; 12(3):. PubMed ID: 32235784
[TBL] [Abstract][Full Text] [Related]
31. Comparison of clinical marking and ultrasound-guided injection of Botulinum type A toxin into the masseter muscles for treating bruxism and its cosmetic effects.
Quezada-Gaon N; Wortsman X; Peñaloza O; Carrasco JE
J Cosmet Dermatol; 2016 Sep; 15(3):238-44. PubMed ID: 26799545
[TBL] [Abstract][Full Text] [Related]
32. Masseteric hypertrophy: considerations regarding treatment planning decisions and introduction of a novel surgical technique.
Pary A; Pary K
J Oral Maxillofac Surg; 2011 Mar; 69(3):944-9. PubMed ID: 21195532
[No Abstract] [Full Text] [Related]
33. Botulinum toxin a for lower facial contouring: a prospective study.
Yu CC; Chen PK; Chen YR
Aesthetic Plast Surg; 2007; 31(5):445-51; discussion 452-3. PubMed ID: 17674088
[TBL] [Abstract][Full Text] [Related]
34. Does Botulinum Toxin Injection into Masseter Muscles Affect Subcutaneous Thickness?
Park G; Choi YC; Bae JH; Kim ST
Aesthet Surg J; 2018 Feb; 38(2):192-198. PubMed ID: 29117291
[TBL] [Abstract][Full Text] [Related]
35. Complications of botulinum toxin injection for masseter hypertrophy: Incidence rate from 2036 treatments and summary of causes and preventions.
Peng HP; Peng JH
J Cosmet Dermatol; 2018 Feb; 17(1):33-38. PubMed ID: 29250900
[TBL] [Abstract][Full Text] [Related]
36. Botulinum toxin for masseter reduction in Asian patients.
Ahn J; Horn C; Blitzer A
Arch Facial Plast Surg; 2004; 6(3):188-91. PubMed ID: 15148129
[TBL] [Abstract][Full Text] [Related]
37. Painful unilateral temporalis muscle enlargement: reactive masticatory muscle hypertrophy.
Katsetos CD; Bianchi MA; Jaffery F; Koutzaki S; Zarella M; Slater R
Head Neck Pathol; 2014 Jun; 8(2):187-93. PubMed ID: 23900775
[TBL] [Abstract][Full Text] [Related]
38. [The use of botulinum toxin type A in masseter muscle hypertrophy: long-term effects and lasting improvement].
Aydil B; Başaran B; Unsaler S; Süoğlu Y
Kulak Burun Bogaz Ihtis Derg; 2012; 22(5):249-53. PubMed ID: 22991984
[TBL] [Abstract][Full Text] [Related]
39. Treatment of masseteric hypertrophy with botulinum toxin: a report of two cases.
Baş B; Ozan B; Muğlali M; Celebi N
Med Oral Patol Oral Cir Bucal; 2010 Jul; 15(4):e649-52. PubMed ID: 20173718
[TBL] [Abstract][Full Text] [Related]
40. Intramuscular nerve distribution of the masseter muscle as a basis for botulinum toxin injection.
Kim DH; Hong HS; Won SY; Kim HJ; Hu KS; Choi JH; Kim HJ
J Craniofac Surg; 2010 Mar; 21(2):588-91. PubMed ID: 20489458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
